- 10 Indian stocks to watch: Sun Pharma, Bharti Airtel, ONGC, moreDrugmakers Cipla Ltd, Sun Pharmaceuticals may miss quarterly estimates: StarMineSun Pharma Q3 net profit jumps 74% to Rs 1,531 crore, beats analysts' expectationsBSE Sensex stays flat, Ranbaxy Laboratories, Sun Pharma Res rise, ABG Shipyard soars 14 pct
Shares in Sun Pharmaceuticals Industries gain 1.5 per cent after the company got U.S. Food and Drug Administration approval to sell a drug to treat Osteoporosis, a bone-weakening disease.
Currently the drug, Ibandronate Sodium, is marketed by Roche under the brand name Bovina.
"Bovina generated an annual sales of $82 million in 2012. Currently, Sun Pharma is the only generic player to have final approval for this product," brokerage Sharekhan said in a note on Wednesday.
More players would be able to sell the drug after its patent expiry on Sept. 2, 2014, Sharekhan said.